Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging

Conditions

• Myocardial Suppression

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Accepted

Interventions

• Fast + High-fat low-carbohydrate diet — OTHER
  Participants will be instructed to follow a strict HFLC diet starting on the morning of the day before the visit and to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications.
• Fast + Empagliflozin — COMBINATION_PRODUCT
  Participants will be instructed to fast for 14 hours, starting at 7pm the day before the visit. Participants will be allowed to drink water and take their medications. Participants will also be instructed to take an oral dose of 50 mg of empagliflozin at 7am the morning before the experimental visit and on the day of the experimental visit.

Study Details

The overall objective of this study is to assess if the empagliflozin has the potential to substitute the high fat low carb (HFLC) diet for the preparation of cardiovascular FDG-PET studies.

Key Dates

Start date

Jun 1, 2024

Status verified

Oct 2024

Primary completion

Nov 1, 2024

Completion

Nov 1, 2024

Study Design

Enrollment

16 participants (actual)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

DIAGNOSTIC

Primary Outcome Measure

Levels of serum Beta-hydroxybutyrate (BHB) mmol/L [ Time Frame: 1 day ]